| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514700300 | Type I diabetes | 36 |
| 20100273704 | METHODS OF MODULATING CELLULAR HOMEOSTATIC PATHWAYS AND CELLULAR SURVIVAL - The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer. | 10-28-2010 |
| 20100279932 | BINDING CONSTRUCTS AND METHODS FOR USE THEREOF - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins. | 11-04-2010 |
| 20110003741 | NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE - The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability. | 01-06-2011 |
| 20110046055 | THERAPEUTIC AGENT FOR DIABETES - Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to treat diabetes, in particular type 2 diabetes, inter alia to treat diabetes in a patient who is concurrently administered with insulin. | 02-24-2011 |
| 20110053840 | ALLELE AND ISOTOPE-SPECIFIC INTERVENTION ON MHC CLASS II MOLECULES ASSOCIATED WITH AUTOIMMUNE DISEASES BY MEANS OF PEPTIDES - The present invention relates to a peptide for the treatment or prophylaxis of an autoimmune disease, a nucleic acid molecule coding for said peptide, a pharmaceutical composition comprising the peptide and/or the nucleic acid molecule, and to a method for the treatment and/or prophylaxis of an autoimmune disease. | 03-03-2011 |
| 20110082080 | COMPOSITIONS AND METHODS OF USING THE HUMAN PROISLET PEPTIDE RECEPTOR - Methods and compositions related to the use of Human proIslet Peptide Receptor (HIP) are disclosed herein. Compositions include peptides and peptidomimetics capable of binding the HIP receptors. Methods include screening assays for ligands of receptors and proteins involved in islet cell signaling. | 04-07-2011 |
| 20110112015 | USE OF GLIS3 FOR PREPARING FUNCTIONAL PANCREATIC BETA-CELLS - The present invention relates to a method of diagnosis of neonatal diabetes, congenital hypothyroidism and congenital glaucoma, comprising detecting the presence of a mutation in the GLIS3 gene and to a method for preparing functional pancreatic beta-cells by culturing human multipotent or pluripotent cells, such as embryonic stem cells (ES-cells) or human somatic stem cells in a culture medium comprising a effective amount of GLIS3 to induce said cells differenciation into functional pancreatic beta-cells producing insulin. It also relates to a pharmaceutical composition comprising GLIS3 as active ingredient. | 05-12-2011 |
| 20110112016 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM - A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T | 05-12-2011 |
| 20110112017 | COMPOSITIONS, METHODS AND USES FOR TREATING DIABETES - Embodiments herein concern compositions and methods for treating diabetes in a subject. | 05-12-2011 |
| 20110263495 | METHODS AND KITS FOR TREATING DISEASE BY ADMINISTERING INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-2 - The present invention is directed to methods of treating Type I diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. | 10-27-2011 |
| 20110288016 | PREPARATION FOR USE OF ASPARTATE AND VITAMIN B12 OR BIOTIN FOR REGULATING KETONE BODIES - It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents. | 11-24-2011 |
| 20120021981 | COMPOSITIONS TO PREVENT AND TREAT TYPE-1 DIABETES - The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications. | 01-26-2012 |
| 20120035106 | USE OF APL-TYPE PEPTIDE FOR TREATING INTESTINAL INFLAMMATORY DISEASES AND TYPE 1 DIABETES - The present invention is related with the field of the medicine, particularly with the use of an APL peptide or its analogues derived from the human heat shock protein of 60 kDa, for the manufacture of a pharmaceutical composition for the treatment of Crohn's disease, ulcerative colitis and diabetes mellitus type 1. This peptide is biodistributed into the gastrointestinal tract and also promotes the induction of apoptosis in activated intestinal lamina propria and peripheral blood T cells of patients with Crohn's disease. Furthermore, this peptide induces apoptosis in mononuclear cells of patients with diabetes mellitus type 1. | 02-09-2012 |
| 20120225813 | COMPOSITIONS, METHODS AND USES FOR TREATMENT OF TYPE 1 DIABETES - Embodiments herein concern compositions and methods for treating diabetes in a subject. | 09-06-2012 |
| 20120232004 | Methods for Treating Autoimmune Disorders, and Reagents Related Thereto - The invention generally relates to improved methods for the treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease. | 09-13-2012 |
| 20130150293 | METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN - The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product. | 06-13-2013 |
| 20130157943 | METHOD AND USE OF PEPTIDE ANTAGONISTS OF ZONOLIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 06-20-2013 |
| 20130274187 | PEPTIDES AND METHODS OF USING SAME - We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases. | 10-17-2013 |
| 20140066373 | TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS - Methods are provided of treating or preventing diabetes in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. Methods are also provided of increasing insulin secretion in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. | 03-06-2014 |
| 20140128321 | METHOD AND USE OF PEPTIDE ANTAGONISTS OF ZONULIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 05-08-2014 |
| 20140155324 | NOVEL PEPTIDES AND USES THEREOF IN THERAPEUTIC METHODS - The invention relates to polypeptides exhibiting metabolic-modulating as well as immunomodulatory properties, nucleic acids encoding them, compositions comprising them, and methods of treating metabolic disorders and/or immune-related disorders comprising their administration and to their use in preparing pharmaceutical compositions for the treatment, amelioration, prophylaxis or delaying the onset of at least one of a metabolic disorder and an immune-related disorder. | 06-05-2014 |
| 20140162948 | FORMULATION FOR INCREASING BIOAVAILABILITY OF NEURTURIN - The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability. | 06-12-2014 |
| 20140249081 | NANOPARTICLE PEPTIDE COMPOSITIONS - The present invention relates to amylin peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of blood glucose regulation. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise glutathione; and at least one amylin peptide that is non-covalently bound to the corona. | 09-04-2014 |
| 20140274892 | REDUCING THE RISK OF AUTOIMMUNE DISEASE - The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da. | 09-18-2014 |
| 20140303080 | N-ACYLDIPEPTIDE DERIVATIVES AND THEIR USES - N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject. | 10-09-2014 |
| 20140357557 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-JAK inhibitor conjugates are described herein. | 12-04-2014 |
| 20150011471 | REGENERATION OF ISLET BETA CELLS BY HSP60 DERIVED PEPTIDES - The present invention provides compositions for use in the treatment of long-established type 1 diabetes (T1D) using peptides and analogs of heat shock protein 60 (Hsp60). The invention is exemplified using DiaPep277, a peptide analog of human Hsp60, which is shown to induce increase in plasma C-peptide and regeneration of islet beta cells. The invention further relates to regimens useful for treatment of long established T1D in patients having no demonstrable islet beta cell-function. | 01-08-2015 |
| 20150111821 | MUTATED FIBROBLAST GROWTH FACTOR (FGF) 1 AND METHODS OF USE - The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1c-binding protein, a β-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided. | 04-23-2015 |
| 20150133375 | PEPTIDES AND METHODS OF USING SAME - We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases. | 05-14-2015 |
| 20150299292 | METHODS AND COMPOSITIONS FOR MODULATING TOSO ACTIVITY - The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein. | 10-22-2015 |
| 20150352187 | COMPOSITION HAVING TISSUE-REPAIRING ACTIVITY, AND USE THEREFOR - A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan. | 12-10-2015 |
| 20160060299 | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders. | 03-03-2016 |
| 20160060317 | NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE - The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability. | 03-03-2016 |
| 20160075737 | SYNTHETIC ANTI-INFLAMMATORY PEPTIDES AND USE THEREOF - The present invention is directed to synthetic anti-inflammatory peptides and use thereof in the treatment and prevention of inflammatory and fibrotic conditions. Specifically, the invention relates in some embodiments to short isolated peptides having the amino acid sequence Phe-Lys-Glu (FKE), Tyr-Lys-Glu (YKE) or comprising a plurality of these sequences that may be flanked by Ala/Gly (A/G) linkers. The invention further relates in some embodiments to methods for inhibiting scar formation and for treating and alleviating IL-10 dependent conditions. | 03-17-2016 |
| 20160130325 | METHOD FOR PRODUCING HYPO-METALLATED REDOX-ACTIVE METALLOTHIONEIN PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention relates to method for producing hypo-metallated redox-active metallothionein (MT) proteins, pharmaceutical compositions containing the proteins, and uses the pharmaceutical compositions for treatment of conditions originating from elevated intracellular oxidative stress and/or dis-balanced intracellular redox-potential and/or redox-potential-dependent imbalance of metal ions. | 05-12-2016 |
| 20160146807 | CXCR4 AND ROBO1 EXPRESSION AS MARKERS FOR AUTOIMMUNE DIABETES - CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes. | 05-26-2016 |
